MCC22

a novel bivalent compound containing a CCR5 antagonist and mu opioid receptor (MOR) agonist pharmacophores linked through a 22-atom spacer

Also Known As:

7V-(3-(4-(4-carbamoylbenzyl)piperidin- 1-yl)propyl)-N-(3 -chloro-4-methylphenyl)- 1-(22-(((4aS,7S,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,3,4,4a,5,6,7,7a-octahydro-lH-4,12-methanobenzofuro(3,2-e)isoquinolin-7-yl)amino)-5,18,22-trioxo-3,20-dioxa-6,17-di

Networked: 3 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - MCC22: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - MCC22: 3

Experts

1.	Akgün, Eyup: 3 articles (11/2019 - 01/2018)
2.	Lunzer, Mary M: 3 articles (11/2019 - 01/2018)
3.	Portoghese, Philip S: 3 articles (11/2019 - 01/2018)
4.	Cataldo, Giuseppe: 2 articles (11/2019 - 07/2018)
5.	Olson, Julie K: 2 articles (11/2019 - 07/2018)
6.	Simone, Donald A: 2 articles (11/2019 - 07/2018)
7.	Erb, Samuel J: 1 article (11/2019)
8.	Luong, Nhungoc: 1 article (11/2019)
9.	Belcher, John D: 1 article (07/2018)
10.	Vercellotti, Gregory M: 1 article (07/2018)

Related Diseases

1.	Pain (Aches) 11/01/2019 - "Given the exceptional potency of MCC22 without tolerance or reward, MCC22 has the potential to vastly improve management of chronic pain due to CIPN. " 07/01/2018 - "In view of the extraordinary potency of MCC22 without tolerance, MCC22 and similar compounds may vastly improve the management of pain associated with SCD." 11/01/2019 - "We investigated the efficacy of a novel bivalent ligand, MCC22, for the treatment of pain arising from CIPN. " 01/01/2018 - "Daily treatment with MCC22 also led to a cumulative analgesic effect, reducing the daily baseline pain level. " 01/01/2018 - "These findings suggest that MCC22 or similar compounds could be used to treat the pain associated with inflammatory arthritis and related conditions, while minimizing the risks typically associated with chronic opioid use."
2.	Arthritis (Polyarthritis) 01/01/2018 - "We evaluated the efficacy of MCC22 in the K/B.g7 T-cell receptor transgenic mouse model of spontaneous inflammatory arthritis. " 01/01/2018 - "Ankle thickness and arthritis scores were not affected by MCC22. " 01/01/2018 - "Our findings demonstrate that MCC22 provides highly potent analgesia and improved functional outcomes in a model of inflammatory arthritis, without inducing typical opioid tolerance. " 01/01/2018 - "These findings suggest that MCC22 or similar compounds could be used to treat the pain associated with inflammatory arthritis and related conditions, while minimizing the risks typically associated with chronic opioid use."
3.	Neuralgia (Stump Neuralgia) 11/01/2019 - "The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward."
4.	Hyperalgesia 11/01/2019 - "Cisplatin produced mechanical hyperalgesia that was decreased dose-dependently by MCC22 given by intrathecal (ED50 = 0.004 pmol) or i.p. " 11/01/2019 - "The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward."
5.	Sickle Cell Anemia (Hemoglobin S Disease) 07/01/2018 - "Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease."

Related Drugs and Biologics

1.	Ligands
2.	Opioid Analgesics (Opioids)
3.	Chemokine Receptors
4.	mu Opioid Receptors (mu Opioid Receptor)
5.	Cisplatin (Platino)
6.	Analgesics (Analgesic Drugs)

Related Therapies and Procedures

1.	Analgesia